Home > Pulmonology > ERS 2019 > Novel Developments in Infectious Disease > Long-term Azithromycin Decreases Exacerbations in Primary Ciliary Dyskinesia

Long-term Azithromycin Decreases Exacerbations in Primary Ciliary Dyskinesia

Presented By
Dr Helene Kobbernagel, Rigshospitalet Copenhagen, Denmark
ERS 2019

The BESTCILIA trial presented strong evidence that a low dose of azithromycin over a period of 6 months can help prevent exacerbation in primary ciliary dyskinesia (PCD) and reduce pathogenic bacteria in the sputum.

PCD is a rare condition. The signs of this congenital disease start in neonates or young children, and it progresses throughout adulthood. Symptoms include chronic rhinosinusitis, recurrent otitis media, conductive hearing impairment, chronic productive cough, as well as infection and inflammation of the lower respiratory tract [1]. Currently, data on PCD is still scarce.

Dr Helene Kobbernagel (Rigshospitalet Copenhagen, Denmark) presented the results of the randomised controlled, European, multicentre BESTCILIA trial [2]. The trial investigated efficacy and safety of azithromycin as a maintenance therapy to prevent respiratory exacerbations of PCD. Participants (n=90), aged 7-50 years, were randomised to receive either placebo (n=41) or...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on